MTNB
Matinas BioPharma Holdings, Inc.Company Information
- Company Name
- Matinas BioPharma Holdings, Inc.
- CIK
- CIK0001582554
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- MTNB: NYSE
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- MTNB
SEC filing data through
Insider Sentiment
- Last purchase
- 2020-08-21
- Last sale
- —
- Shares purchased (TTM)
- 298,000
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 325,055
- Shares outstanding
- 6,406,191
- Ownership
- 5.07%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- -21.89%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 1 | 2 | 4 | 5 | 7 | 7 | 7 | 10 | 4 | 1 | 5 | 6 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 1 | 3 | 4 | 6 | 7 | 8 | 8 | 12 | 15 | 10 | 16 | 20 | ||||||
| Marketable Securities Current | - | - | - | - | - | - | - | 1 | 10 | 7 | 9 | 12 | ||||||
| Restricted Cash Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | ||||||
| Property Plant And Equipment Net | - | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | ||||||
| Assets Held In Trust Noncurrent | - | - | - | 0 | 0 | - | - | - | - | - | - | - | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | ||||||
| Finance Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Assets Noncurrent | 2 | 3 | 3 | 4 | 4 | 4 | 5 | 9 | 9 | 9 | 10 | 10 | ||||||
| Intangible Assets Net Excluding Goodwill | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | ||||||
| Goodwill | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | ||||||
| Restricted Cash Noncurrent | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 3 | 6 | 7 | 10 | 11 | 12 | 13 | 21 | 24 | 20 | 25 | 30 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | ||||||
| Accrued Liabilities And Other Liabilities | 1 | 1 | 0 | - | - | - | 2 | - | - | - | 1 | - | ||||||
| Operating Lease Liability Current | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Accrued Liabilities Current | - | 1 | - | 1 | 1 | 1 | - | 1 | 1 | 1 | 1 | 2 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 1 | 2 | 1 | 1 | 2 | 2 | 3 | 2 | 2 | 2 | 3 | 3 | ||||||
| Finance Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Deferred Income Tax Liabilities Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Liability Noncurrent | - | 0 | 1 | 1 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Finance Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Noncurrent | 0 | 1 | 1 | 2 | 2 | 4 | 2 | 3 | 3 | 3 | 3 | 3 | ||||||
| Derivative Liabilities | - | - | - | - | - | 1 | - | - | - | - | - | - | ||||||
| Liabilities | 2 | 3 | 2 | 3 | 4 | 6 | 5 | 5 | 5 | 5 | 6 | 7 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Additional Paid In Capital Common Stock | 216 | 216 | 216 | 215 | 214 | 208 | 207 | 207 | 206 | 196 | 195 | 194 | ||||||
| Stockholders Equity | 2 | 3 | 5 | 6 | 8 | 6 | 8 | 16 | 19 | 15 | 19 | 23 | ||||||
| Retained Earnings Accumulated Deficit | -214 | -213 | -211 | -209 | -207 | -201 | -200 | -191 | -187 | -181 | -176 | -170 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | - | - | - | - | - | - | - | - | -0 | -0 | -0 | -0 | ||||||
| Liabilities And Stockholders Equity | 3 | 6 | 7 | 10 | 11 | 12 | 13 | 21 | 24 | 20 | 25 | 30 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | - | - | - | - | - | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 250 | 250 | 250 | 250 | 500 | 500 | 250 | 500 | ||||||
| Common Stock Shares Issued | 6 | 6 | 6 | 6 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | ||||||
| Shares Outstanding | 6 | 6 | 6 | 6 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialMatinas BioPharma Holdings, Inc. (MTNB) — SEC Financial Statements & Analysis
Matinas BioPharma Holdings, Inc. (MTNB) is a pharmaceutical preparations company, incorporated in DE. Matinas BioPharma Holdings, Inc. trades on NYSE as: MTNB. Matinas BioPharma Holdings, Inc. (MTNB)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Matinas BioPharma Holdings, Inc. carries a market cap of $3.92M, a P/E ratio of -0.59x, a P/B ratio of 2.18x, a P/S ratio of 42.82x, an enterprise value of $3.17M, and an EV/EBITDA multiple of -0.47x. On profitability, it posts an operating margin of -2168.43%, a net margin of -2093.25%, a Return on Equity (ROE) of -141.23%, a Return on Assets (ROA) of -90.20%, and a Return on Invested Capital (ROIC) of -603.17%. Per share, it reports EPS of $-1.04, diluted EPS of $-1.04, free cash flow per share of $-1.00, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -65.88% year-over-year, and EPS growth of -72.90% year-over-year. On the balance sheet, it maintains a current ratio of 0.85x, a quick ratio of 0.60x, working capital of $-207.00K, a debt-to-equity ratio of 0.90x, a debt ratio of 0.47, free cash flow of $-6.42M (TTM), and net debt of $-755.00K. Figures sourced from SEC EDGAR.
- Market Cap
- $3.92M
- P/E TTM
- -0.59x
- EPS TTM
- $-1.04
- P/B TTM
- 2.18x
- ROE TTM
- -141.23%
- ROA TTM
- -90.20%
- Debt To Equity
- 0.90x
- Free Cash Flow TTM
- $-6.42M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Matinas BioPharma Holdings, Inc. in?
Matinas BioPharma Holdings, Inc. (MTNB) operates in the Pharmaceutical Preparations industry.
What exchange does MTNB trade on?
Matinas BioPharma Holdings, Inc. (MTNB) trades on the NYSE.
Where is Matinas BioPharma Holdings, Inc. incorporated?
Matinas BioPharma Holdings, Inc. is incorporated in DE.
When was Matinas BioPharma Holdings, Inc. (MTNB)'s most recent SEC filing?
Matinas BioPharma Holdings, Inc. (MTNB)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is MTNB's market cap?
Matinas BioPharma Holdings, Inc. (MTNB) has a market capitalization of $3.92M as of 2026-06-30.
What is MTNB's EPS (earnings per share)?
Matinas BioPharma Holdings, Inc. (MTNB)'s trailing twelve month EPS is $-1.04 as of 2026-06-30.
What is MTNB's ROE (return on equity)?
Matinas BioPharma Holdings, Inc. (MTNB)'s trailing twelve month Return on Equity (ROE) is -141.23% as of 2026-06-30.
What is MTNB's ROA (return on assets)?
Matinas BioPharma Holdings, Inc. (MTNB)'s trailing twelve month Return on Assets (ROA) is -90.20% as of 2026-06-30.
What is MTNB's ROIC (return on invested capital)?
Matinas BioPharma Holdings, Inc. (MTNB)'s trailing twelve month Return on Invested Capital (ROIC) is -603.17% as of 2026-06-30.
What is MTNB's EV/EBITDA?
Matinas BioPharma Holdings, Inc. (MTNB)'s trailing twelve month EV/EBITDA is -0.47x as of 2026-06-30.